Results of the Treatment of Prostatic Cancer

Abstract

Ninety-five patients with prostatic carcinoma first treated from 1963 to 1972 were followed through 1975. Age of the patients ranged from 45 to 85 years old with an average of 68 years old. Histological diagnosis was adenocarcinoma in all patients; 64 patients had well differentiated type and 31 had poorly differentiated type. Five patients were classified in stage T0NxM0, one in stage T12 NxMo, 45 in stage T3. 4NxMo, and 44 in stae To. 4NxM1. All patients were treated by synthetic estrogen (hexestrol). Castration was done in combination with estrogen therapy in 74 patients.Patients with non-metastatic prostatic carcinoma showed a little better relative survival rates than patients with metastatic prostatic carcinoma; 5-year relative survival rates were 55% (S. E. 10%) for non-metastatic prostatic carcinoma and 35% (S. E. 10%) for metastatic prostatic carcinoma.Survival rates of patients with prostatic carcinoma of poorly differentiated type were significantly worse than those of well differentiated type; 5-year relative survival rates were 10% (S. E. 7%) for poorly differentiated type and 65% (S. E. 9%) for well differentiated type.As for the dosis of synthetic estrogen, 41 patients were maintained on 100 mg of hexestrol daily and 54

Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective

“…However, the Huggins’ mantra had relatively little effect on the Japanese medical community and PADT continued to be used, with little resistance, for numerous LPC and LAPC cases. ( 10–12 ) The fact that cardiovascular adverse reactions to administration of estrogen, which became a serious issue in clinical trials carried out by the US Veterans Administration Cooperative Urological Research Group (VACURG), ( 13 ) were relatively uncommon in Japan is believed to have played no small part in this. Another factor that caused a different response to PADT in Japan than in Western countries may have been that clinical tests conducted in Japan have shown PADT to be effective against LPC and LAPC.…”

Adverse Effects during Endocrine Therapy for Prostatic Carcinoma with a High Dose of Estrogen

“…Adverse effects of the endocrine therapy were reported by many investigators in Japan. Death as mostly caused by the carcinoma [14,15].…”

Epidemiologie des Prostatakarzinoms

“…Bezieht man jedoch in Japan die Inzidenz auf alle hospitalisierten Patienten mit Prostataerkrankungen, so liegt die Inzidenz bei 14,8% (unpublizierte Daten der Keio-Universität Tokio). Ähnlich wie beim latenten Karzinom liegt die Häufigkeit des inzidentalen, bei der Prostatektomie überraschenderweise gefundenen Karzinoms in Japan bei 5,3%, unterscheidet sich damit also nicht signifikant von den Daten aus anderen Ländern (Takayasu et al, 1978…”